Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -141.28% is 27% above its 5-year average of -194.60%, near the high end of its 5-year range (-616.25%–-50.33%).
1.90% above its 12-month average of -144.02%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -173.92%.
NET PROFIT MARGIN
-141.28%
NET PROFIT MARGIN AVG TTM
-144.02%
NET PROFIT MARGIN AVG 3Y
-125.41%
NET PROFIT MARGIN AVG 5Y
-194.60%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.90%
CURRENT VS 3Y AVG
-12.66%
CURRENT VS 5Y AVG
+27.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-54238.46%
vs the sector median at left
Lifeward Ltd.
Market Cap
$10.10M
Net Profit Margin
-141.28%
TTM Avg
-144.02%
3Y Avg
-125.41%
5Y Avg
-194.60%
Market Cap
$10.10M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$10.01M
Net Profit Margin
-90116.36%
TTM Avg
-139631.82%
3Y Avg
-71156.88%
5Y Avg
-48680.54%
Market Cap
$10.23M
Net Profit Margin
0.00%
TTM Avg
-496.48%
3Y Avg
-440.58%
5Y Avg
-356.69%
Market Cap
$9.77M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-312.43%
5Y Avg
-391.43%
Market Cap
$10.40M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$9.79M
Net Profit Margin
-106283.32%
TTM Avg
-41799.65%
3Y Avg
-23818.56%
5Y Avg
-17447.75%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lifeward Ltd. (LFWD) | $10.10M | -141.28% | -144.02% | -125.41% | -194.60% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.10M | 0.00% | 0.00% | 0.00% | 0.00% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.01M | -90116.36% | -139631.82% | -71156.88% | -48680.54% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.23M | 0.00% | -496.48% | -440.58% | -356.69% |
| Valion Bio, Inc. (VBIO)vs › | $9.77M | 0.00% | 0.00% | -312.43% | -391.43% |
| MetaVia Inc. (MTVA)vs › | $9.82M | 0.00% | 0.00% | 0.00% | 0.00% |
| Polyrizon Ltd. (PLRZ)vs › | $10.80M | N/A | 0.00% | 0.00% | 0.00% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.40M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ainos, Inc. (AIMD)vs › | $9.79M | -106283.32% | -41799.65% | -23818.56% | -17447.75% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.46M | N/A | -2424.09% | -1624.47% | -1082.98% |
Operating Margin
-76.7%
Net Profit Margin
-141.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -173.92% |
| 2026-03-31 | -275.12% |
| 2025-12-31 | -105.25% |
| 2025-09-30 | -51.17% |
| 2025-06-30 | -114.64% |
| 2025-03-31 | -96.03% |
| 2024-12-31 | -202.49% |
| 2024-09-30 | -50.33% |
| 2024-06-30 | -64.17% |
| 2024-03-31 | -118.80% |
| 2023-12-31 | -81.91% |
| 2023-09-30 | -171.04% |
| 2023-06-30 | -347.20% |
| 2023-03-31 | -351.30% |
| 2022-12-31 | -243.83% |
| 2022-09-30 | -616.25% |
| 2022-06-30 | -283.18% |
| 2022-03-31 | -496.58% |
| 2021-12-31 | -310.63% |
| 2021-09-30 | -135.65% |
| 2021-06-30 | -218.73% |
